Avacincaptad Pegol
Recommended OphthalmologyAuthority RequiredFirst-line line
Treatment of adult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who have an intact fovea and where central vision is threatened by GA lesion growth.
1
Submissions
2026–26
On the record
Redacted
ICER range
commercial-in-confidence
Redacted
Cost basis
Decision on record
- Meeting Mar 2026 Recommended Geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
Access path
- Mar 2026Recommended · restricted
vs best supportive care
- PBS listing · Authority Required
RecommendedDeferredNot recommended
Cost-effectiveness
ICER values redacted (commercially sensitive). Economic model presented but ICER not disclosed in public summary document.
The PBAC considered that the claim of superior comparative effectiveness to BSC was reasonable but the magnitude of the effect on delaying vision loss was uncertain. PBAC · 2026
Decision context
PopulationAdult patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who have an intact fovea and where central vision is threatened by GA lesion growth.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2026 | Recommended · restricted | best supportive care | — | RCT |